SkinHealth Systems Inc. 8-K

What Happened
SkinHealth Systems, Inc. (SKIN) filed an 8-K reporting the results of its virtual annual meeting held June 10, 2026. At the April 16, 2026 record date there were 129,584,184 shares of Class A common stock outstanding; 93,406,914 shares (≈72.08%) were present or represented by proxy, constituting a quorum. Stockholders elected nine directors to one‑year terms (expiring at the 2027 annual meeting): Brenton L. Saunders; Pedro Malha; E. Scott Beattie; Stephen J. Fanning; Michelle Kerrick; Brian Miller; Doug Schillinger; Sachin Shridharani, M.D.; and Kenneth Tripp. Stockholders also ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for FY2026 and approved, on an advisory (non‑binding) basis, the compensation of the company’s named executive officers.

Key Details

• Shares outstanding (Record Date): 129,584,184 Class A shares; Shares voted/present: 93,406,914 (≈72.08% quorum).
• Director votes: all nine nominees elected; example vote counts range from Brian Miller (56,555,107 For; 15,417,370 Withheld) to Sachin Shridharani (71,317,162 For; 655,315 Withheld). Broker non‑votes on director and say‑on‑pay items: 21,434,437.
• Auditor ratification: Deloitte & Touche LLP ratified — 93,125,701 For; 235,673 Against; 45,540 Abstentions.
• Advisory vote on executive compensation (say‑on‑pay): approved — 58,604,735 For; 12,346,541 Against; 1,021,201 Abstentions (plus 21,434,437 broker non‑votes).

Why It Matters
The vote confirms the company’s board slate and continuity of leadership for the coming year and secures Deloitte as the independent auditor for FY2026—both governance items investors watch for oversight and financial reporting stability. The advisory approval of executive compensation passed but included significant opposition and many broker non‑votes, which investors may view as constructive feedback on pay practices even though the vote is non‑binding.